ArticleCardiovascular therapeutics2022

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.

Lingqing Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.